Late-stage mRNA melanoma vaccine shows promise, slowing disease recurrence

A late-stage trial of an mRNA-based cancer vaccine reported that the treatment halted the return of melanoma in patients, providing the first clear evidence of efficacy for this approach.

Merck and Moderna disclosed in August that adding their vaccine, intismeran autogene, to standard therapy slowed both recurrence and spread of melanoma compared with the therapy alone.

The positive outcome has revived optimism that mRNA can be used to train the immune system against other tumor types, though researchers caution that success may not translate across all cancers.

Karen Knudsen, CEO of the Parker Institute for Cancer Immunotherapy, said the data suggest the mRNA vaccine concept is ready for further development, even as the field grapples with unanswered questions about broader applicability.